Introduction: Secreted frizzled related protein 4 (SFRP4) is a modulator of the Wnt pathway. Its secretion is regulated by interleukin-1β. Objectives: Primary objective was to assess the serum levels of SFRP4 in cases of T2DM and normoglycemic (NG) controls. Secondary objectives was to assess the association of serum levels of SFRP4 with chronic micro or macrovascular complications of T2DM. Methods: A case control study conducted after obtaining institutional ethical clearance. Included as cases were those diagnosed with T2DM. Excluded were those who were prediabetics, immunocompromised, endocrinopathies, pregnant and lactating women. Inclusion criteria for NG controls were age >18 years, consenting for participation attending out-patient department for routine care. Exclusion criteria for controls were same as for cases. Serum SFRP4 levels were determined by ELISA using Elabscience kit. Results: From October 2016 till June 2018, included were 98 T2DM cases and 48 NG controls. The mean age of cases was 52.73 yrs (SD: 10.09), and controls 49.92 yrs (SD: 12.344). The median levels of SFRP4 in cases was 1.36 ng/mL (IQR: 0.85, 2.67) and in controls 0.44 ng/mL (IQR: 0.27, 2.58) (p-value < 0.001). In T2DM with (n = 65, 67.7%) versus without (n = 31, 32.3%) any chronic micro/macro vascular complications median serum SFRP4 level was 1.16 ng/mL (IQR: 0.77, 2.44) and 2.24 ng/mL (IQR: 0.92, 4.84) (p-value: 0.03) respectively. Conclusions: There was statistically significantly higher levels of serum SFRP4 levels amongst T2DM cases as compared to NG controls. Cases with chronic complications of T2DM had statistically significant lower levels of serum SFRP4.
All Science Journal Classification (ASJC) codes
- Public Health, Environmental and Occupational Health
- Microbiology (medical)
- Infectious Diseases